Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics SGLT Limits Update | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    SGLT Inhibitors Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This program summary governs quantity limits for selected SGLT inhibitor products and SGLT inhibitor combination products on the Boeing commercial formulary. It defines standard quantities and clinical criteria for approving quantities that exceed the program limit.

    Policy Summary
    PayerPrime Therapeutics
    PolicySGLT Inhibitors Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date05-04-2026
    Next Review DateN/A
    Key ActionFor quantities above the program limit, provide support for the applicable higher-dose or quantity-limit exception.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    30 tabletsCommon quantity limit for a 30-day supply
    60 tabletsSelected combination-product limit
    120 tabletsHighest stated quantity limit
    12 monthsLength of approval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Boeing
    Client formulary

    Quantity-Limit Coverage Criteria

    Quantity-limit approval and exceptions

    Quantity limit for the target agent will be approved when ONE of the following is met.

    Quantity-limit approval

    • Within program limit: The requested quantity (dose) does not exceed the program quantity limit.
    • Exception to program limit

      • No maximum FDA-labeled dose

        • The requested agent does not have a maximum FDA-labeled dose for the requested indication.
        • There is support for therapy with a higher dose for the requested indication.
      • Within maximum labeled dose but quantity exception needed

        • The requested quantity (dose) does not exceed the maximum FDA-labeled dose for the requested indication.
        • There is support for why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.
      • Exceeds maximum FDA-labeled dose

        • The requested quantity (dose) exceeds the maximum FDA-labeled dose for the requested indication.
        • There is support for therapy with a higher dose for the requested indication.

    Provider Requirements and Exception Handling

    Note

    Quantity-Limit Exception Criteria

    The requested quantity (dose) is approved when it does not exceed the program quantity limit, or when it exceeds the limit and one of the exception pathways below is met. Approved quantities have a 12-month length of approval.

    • Exception A: The requested agent does not have a maximum FDA-labeled dose for the requested indication, and documentation supports therapy with a higher dose for that indication.
    • Exception B: The requested quantity does not exceed the maximum FDA-labeled dose for the requested indication, and documentation supports why the requested quantity cannot be achieved using a lower quantity of a higher strength that does not exceed the program quantity limit.
    • Exception C: The requested quantity exceeds the maximum FDA-labeled dose for the requested indication, and documentation supports therapy with a higher dose for that indication.
    Documentation Required

    Documentation Required Above the Program Limit

    For any requested quantity above the program quantity limit, submit supporting documentation establishing the applicable clinical need and satisfying one of the exception pathways. Documentation must address the FDA-labeled dose status, the rationale for the requested quantity, and/or support for higher-dose therapy as applicable.

    Program Background

    This program applies to selected oral SGLT inhibitor products and SGLT inhibitor-containing fixed-dose combinations on the Boeing commercial formulary. Standard quantities are generally set for a 30-day supply, with higher limits for certain combination products, including quantities of 60 or 120 tablets. Requests exceeding the applicable program limit are evaluated against the maximum FDA-labeled dose for the indication and must include clinical support for the requested quantity or higher-dose therapy.

    Initial Quantity-Limit Approval

    Initial quantity-limit approval

    Quantity-limit approval is available when ONE of the following is met.

    • Standard quantity: The requested quantity (dose) does not exceed the program quantity limit.
    • Quantity-limit exception

      • No maximum FDA-labeled dose

        • The requested agent does not have a maximum FDA-labeled dose for the requested indication.
        • Higher-dose therapy is supported.
      • Maximum labeled dose not exceeded

    Product-Specific Quantity Limits

    Quantity limit
    ProductBexagliflozin (Brenzavvy)
    Strength20 mg tablets
    Quantity limit30 tablets per month
    Quantity limit
    ProductDapagliflozin/saxagliptin (Qtern)
    Strength10-5 mg or 5-5 mg tablets
    Quantity limit30 tablets per month
    Policy Summary
    PayerPrime Therapeutics
    PolicySGLT Inhibitors Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date05-04-2026
    Next Review DateN/A
    Key ActionFor quantities above the program limit, provide support for the applicable higher-dose or quantity-limit exception.
    SourceLink
    On This Page
    Quantity-Limit Coverage CriteriaProvider Requirements and Exception HandlingProgram BackgroundInitial Quantity-Limit ApprovalProduct-Specific Quantity Limits
    • If the agent has no maximum FDA-labeled dose for the indication, provide support for therapy with a higher dose.
    • If the requested quantity is within the maximum FDA-labeled dose but exceeds the program limit, explain why the quantity cannot be achieved with a lower quantity of a higher strength that remains within the program limit.
    • If the requested quantity exceeds the maximum FDA-labeled dose, provide support for therapy with a higher dose.
    Denial Risk

    Denial Risk: Insufficient Exception Support

    A quantity above the program limit will be denied when submitted documentation does not establish that one of the specified exception pathways applies. Requests must demonstrate the applicable dose-related rationale and supporting clinical evidence.

    • No exception is established when the requested quantity exceeds the program limit without required supporting documentation.
    • Support must correspond to the requested indication and the applicable FDA-labeled-dose or higher-dose criterion.
  1. The requested quantity (dose) does not exceed the maximum FDA-labeled dose for the requested indication.
  2. Support shows why the quantity cannot be achieved using a lower quantity of a higher strength within the program limit.
  3. Maximum labeled dose exceeded

    • The requested quantity (dose) exceeds the maximum FDA-labeled dose for the requested indication.
    • Higher-dose therapy is supported.
  4. Quantity limit
    ProductDapagliflozin (Farxiga)
    Strength10 mg or 5 mg tablets
    Quantity limit30 tablets per month
    Quantity limit
    ProductEmpagliflozin/linagliptin (Glyxambi)
    Strength10-5 mg or 25-5 mg tablets
    Quantity limit30 tablets per month
    Quantity limit
    ProductSotagliflozin (Inpefa)
    Strength200 mg tablets
    Quantity limit30 tablets per month
    Quantity limit
    ProductSotagliflozin (Inpefa)
    Strength400 mg tablets
    Quantity limit30 tablets per month
    Quantity limit
    ProductEmpagliflozin (Jardiance)
    Strength10 mg or 25 mg tablets
    Quantity limit30 tablets per month
    Quantity limit
    ProductErtugliflozin/metformin (Segluromet)
    Strength2.5-1000 mg tablets
    Quantity limit60 tablets per month
    Quantity limit
    ProductErtugliflozin/metformin (Segluromet)
    Strength2.5-500 mg tablets
    Quantity limit120 tablets per month
    Quantity limit
    ProductErtugliflozin/metformin (Segluromet)
    Strength7.5-1000 mg tablets
    Quantity limit60 tablets per month
    Quantity limit
    ProductErtugliflozin/metformin (Segluromet)
    Strength7.5-500 mg tablets
    Quantity limit60 tablets per month
    Quantity limit
    ProductErtugliflozin (Steglatro)
    Strength15 mg tablets
    Quantity limit30 tablets per month
    Quantity limit
    ProductErtugliflozin (Steglatro)
    Strength5 mg tablets
    Quantity limit60 tablets per month
    Quantity limit
    ProductErtugliflozin/sitagliptin (Steglujan)
    Strength15-100 mg and 5-? mg tablets
    Quantity limit30 tablets per month
    Quantity limit
    ProductEmpagliflozin/metformin (Synjardy)
    Strength12.5-1000 mg tablets
    Quantity limit60 tablets per month
    Quantity limit
    ProductEmpagliflozin/metformin extended release (Synjardy XR)
    Strength10-1000 mg tablets
    Quantity limit60 tablets per month
    Quantity limit
    ProductEmpagliflozin/metformin extended release (Synjardy XR)
    Strength12.5-1000 mg tablets
    Quantity limit60 tablets per month
    Quantity limit
    ProductEmpagliflozin/metformin extended release (Synjardy XR)
    Strength25-1000 mg tablets
    Quantity limit30 tablets per month
    Quantity limit
    ProductEmpagliflozin/metformin extended release (Synjardy XR)
    Strength5-1000 mg tablets
    Quantity limit60 tablets per month
    Quantity limit
    ProductEmpagliflozin/linagliptin/metformin extended release (Trijardy XR)
    Strength12.5-2.5-1000 mg tablets
    Quantity limit60 tablets per month
    Quantity limit
    ProductEmpagliflozin/linagliptin/metformin extended release (Trijardy XR)
    Strength10-5-1000 mg tablets
    Quantity limit30 tablets per month
    Quantity limit
    ProductEmpagliflozin/linagliptin/metformin extended release (Trijardy XR)
    Strength25-5-1000 mg tablets
    Quantity limit30 tablets per month
    Quantity limit
    ProductEmpagliflozin/linagliptin/metformin extended release (Trijardy XR)
    Strength5-2.5-1000 mg tablets
    Quantity limit60 tablets per month
    Quantity limit
    ProductDapagliflozin/metformin extended release (Xigduo XR)
    Strength2.5-1000 mg tablets
    Quantity limit60 tablets per month
    Quantity limit
    ProductDapagliflozin/metformin extended release (Xigduo XR)
    Strength5-500 mg tablets
    Quantity limit30 tablets per month
    Quantity limit
    ProductDapagliflozin/metformin extended release (Xigduo XR)
    Strength5-1000 mg tablets
    Quantity limit60 tablets per month
    Quantity limit
    ProductDapagliflozin/metformin extended release (Xigduo XR)
    Strength10-500 mg tablets
    Quantity limit30 tablets per month
    Quantity limit
    ProductDapagliflozin/metformin extended release (Xigduo XR)
    Strength10-1000 mg tablets
    Quantity limit30 tablets per month